Published in Leuk Lymphoma on May 01, 2002
Acute lymphoblastic leukemia of childhood presenting as aplastic anemia: report of two cases. Rev Bras Hematol Hemoter (2012) 0.79
Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome. J Neurooncol (2005) 1.00
The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients. Lung Cancer (2009) 0.99
Coordinated increase of miRNA-155 and miRNA-196b expression correlates with the detection of the antigenomic strand of hepatitis C virus in peripheral blood mononuclear cells. Int J Mol Med (2011) 0.92
Association of tumor necrosis factor and human leukocyte antigen DRB1 alleles with Graves' ophthalmopathy. Hum Immunol (2004) 0.91
Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen--diagnostic and therapeutic dilemmas. Leuk Lymphoma (2002) 0.91
Manganese superoxide dismutase (MnSOD) gene (Ala-9Val, Ile58Thr) polymorphism in patients with age-related macular degeneration (AMD). Med Sci Monit (2010) 0.91
MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep (2006) 0.90
Coexistence of chronic lymphocytic leukemia and essential thrombocythemia. Leuk Lymphoma (2003) 0.89
Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features. Leuk Lymphoma (2002) 0.87
Successful treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporin A in a patient with chronic granulomatous disease. Ann Hematol (2005) 0.84
[Management of hyperthyroidism with radioactive iodine in end-stage renal disease patients undergoing dialysis]. Pol Arch Med Wewn (2004) 0.83
The effect of antisense oligonucleotide treatment of plasma membrane Ca(+2)-ATPase in PC12 cells. Cell Mol Biol Lett (2004) 0.82
Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia. Hematology (2010) 0.82
Mevalonate pathway modulation is associated with hepatitis C virus RNA presence in peripheral blood mononuclear cells. Virus Res (2009) 0.81
Hodgkin's type of Richter's syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide. Leuk Lymphoma (2003) 0.81
Impact of screening kindreds for SDHD p.Cys11X as a common mutation associated with paraganglioma syndrome type 1. J Clin Endocrinol Metab (2008) 0.81
Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant. Acta Biochim Pol (2008) 0.81
Chronic myelomonocytic leukemia coexisting with B-cell chronic lymphocytic leukemia. Leuk Lymphoma (2003) 0.81
High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement. Leuk Lymphoma (2006) 0.79
Prognostic value of the bone marrow microvessel density in progressive B-cell chronic lymphocytic leukemia. Leuk Lymphoma (2010) 0.79
A unique occurrence of a cerebral atypical teratoid/rhabdoid tumor in an infant and a spinal canal primitive neuroectodermal tumor in her father. J Neurooncol (2003) 0.79
Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status. Leuk Lymphoma (2010) 0.79
Multiple myeloma in a patient with systemic lupus erythematosus, myasthenia gravis and non-familial diffuse palmoplantar keratoderma. Leuk Lymphoma (2004) 0.79
Demographic, Hematologic, and Clinical Features of Myelodysplastic Syndrome Patients: Results from the First Polish Myelodysplastic Syndrome Registry. Acta Haematol (2015) 0.79
Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells. Biochem Cell Biol (2008) 0.78
A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study. Thromb Haemost (2007) 0.78
Therapeutic properties and safety of recombinant factor VIII and factor IX. Pol Arch Med Wewn (2009) 0.77
The cytosol activity of thymidine phosphorylase in endometrial cancer. J Exp Clin Cancer Res (2008) 0.77
[The influence of nitric oxide on the regulation of plasminogen activator inhibitor type 1 and tissue-type plasminogen activator expression]. Postepy Biochem (2005) 0.77
[Expression of bone morphogenetic proteins, matrix metalloproteinases and inhibitors of matrix metalloproteinases in lung cancers and their prognostic significance]. Postepy Biochem (2008) 0.77
The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. Blood Coagul Fibrinolysis (2009) 0.77
Cytotoxic activity of the selected pyridinium salts against murine leukemia L1210. Pharmacol Rep (2007) 0.76
Langerhans cell histiocytosis in a patient with systemic lupus erythematosus: a clonal disease responding to treatment with cladribine, and cyclophosphamide. Leuk Lymphoma (2002) 0.76
Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers. Int J Hematol (2010) 0.76
The activity of thymidine phosphorylase as a new ovarian tumor marker. Gynecol Oncol (2004) 0.76
Pax-8 expression correlates with type II 5' deiodinase expression in thyroids from patients with Graves' disease. Thyroid (2003) 0.76
[Role of lipid rafts in hepatitis C virus life cycle]. Postepy Biochem (2007) 0.76
The study of t-PA, u-PA and PAI-1 genes polymorphisms in patients with abdominal aortic aneurysm. Mol Biol Rep (2014) 0.75
Association analysis of genetic polymorphisms of factor V, factor VII and fibrinogen β chain genes with human abdominal aortic aneurysm. Exp Ther Med (2012) 0.75
Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma. Med Oncol (2012) 0.75
Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy. Med Oncol (2012) 0.75
[Influence of the thymidine phosphorylase (platelet-derived endothelial cell growth factor) on tumor angiogenesis. Catalytic activity of enzyme inhibitors]. Postepy Biochem (2010) 0.75
Exposure to polychlorinated naphthalenes affects GABA-metabolizing enzymes in rat brain. Environ Toxicol Pharmacol (2005) 0.75
[The assessment of platelet function in patients with essential thrombocythemia]. Pol Merkur Lekarski (2008) 0.75
[The thymidine phosphorylase as the platelet-derived endothelial cell growth factor of endometrial cancer]. Ginekol Pol (2009) 0.75
Immune thrombocytopenia in patients with chronic lymphocytic leukemia treated with cladribine-based regiments or chlorambucil--follow-up of PALG-CLL randomized trials. Eur J Haematol (2013) 0.75
Cytotoxic effect of cyclosporin A alone and in combination with 2-chlorodeoxyadenosine against P388 murine leukemia in vivo. Med Sci Monit (2002) 0.75
[Evaluation of bone mineral density in women with chronic liver diseases during perimenopausal period]. Pol Arch Med Wewn (2006) 0.75
Assessment of rotation thromboelastometry parameters in patients with essential thrombocythemia at diagnosis and after hydroxyurea therapy. Blood Coagul Fibrinolysis (2016) 0.75
[Thrombotic thrombocytopenic purpura in pregnancy. A case report]. Ginekol Pol (2008) 0.75
Enhanced P53 and BAX gene expression and apoptosis in A549 cells by cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Invest New Drugs (2005) 0.75
Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia. Leuk Lymphoma (2007) 0.75
Repeated ventricular. Cardiol J (2007) 0.75
[Disseminated intravascular coagulation in abdominal aortic aneurysm--case report]. Pol Merkur Lekarski (2009) 0.75
[Influence of the selected pyrimidine compounds on the activity of thymidine phosphorylase from normal and tumor endometrial cells]. Ginekol Pol (2009) 0.75
[Cancer antigen 125 as a marker of ascites in patients with liver cirrhosis]. Pol Merkur Lekarski (2004) 0.75
[Significance of MDM2 protein in the cell cycle]. Postepy Biochem (2005) 0.75
[Correlations between ROTEM fibrinolytic activity and t-PA, PAI-1 levels in patients with newly diagnosed multiple myeloma]. Pol Merkur Lekarski (2014) 0.75
[Regulation of gene expression by nitric oxide]. Postepy Biochem (2007) 0.75